Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157823 | 0.86 | KDM4E (0.39) | CHEK1CHRM1KDM4EHTTATM | |
| SCHEMBL2871147 | 0.85 | KDM4E (0.36) | CHEK1CHRM1KCNH2KDM4EHTT | |
| SCHEMBL2249120 | 0.85 | NR1I2 (0.39) | CHEK1CHRM1KDM4EHTTATM | |
| SCHEMBL14136639 | 0.85 | SLC6A2 (0.43) | CHEK1CHRM1KCNH2SLC6A4SLC6A2 | |
| SCHEMBL2877238 | 0.85 | NR1I2 (0.41) | CHEK1KCNH2KDM4EHTTATM | |
| SCHEMBL14136984 | 0.84 | POLB (0.40) | KDM4EATM | |
| SCHEMBL2877241 | 0.84 | CHEK1 (0.38) | CHEK1CHRM1KCNH2KDM4EHTT | |
| Lithium Ion SCHEMBL2249121 | 0.83 | KDM4E (0.37) | CHEK1CHRM1KCNH2KDM4EHTT | |
| SCHEMBL2425688 | 0.83 | KDM4E (0.50) | CHEK1KDM4EHTTATM | |
| SCHEMBL2430637 | 0.83 | KDM4E (0.50) | CHEK1KDM4EHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | CHEK1 3357/4885CHRM1 4729/4885KCNH2 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.